Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

Phenytoin (diphenylhydantoin)

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (interstitial lung disease/ILD)
I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.e

Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.h

Lymphocytic interstitial pneumonia
I.l

Lung nodule or nodules

XLI - Pulmonary edema - Acute lung injury - ARDS

XLI.e

ARDS - Acute lung injury

XLII - Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a

Alveolar hemorrhage (AH), diffuse AH (DAH)
XLII.b

Pneumorenal syndrome (w/wo ANCAs)

XLIII - Airway involvement

XLIII.a

Bronchospasm - Wheezing - Asthma
XLIII.ab

Cough (lone)
XLIII.ag

Obstructive airway dysfunction (see also IVc, XVx)

XLVI - Pulmonary vasculopathy

XLVI.d

Pulmonary vasculitis or capillaritis

XLVII - Mediastinal involvement

XLVII.a

Lymphadenopathy (intrathoracic)
XLVII.b

Lymphadenopathy with reactive changes
XLVII.m

Malignant lymphoma

XLIX - Systemic/Distant conditions, syndromes and reactions

XLIX.a

DRES syndrome - DRESS-like reaction
XLIX.d

Lupus - Lupus syndrome (see also Vd)
XLIX.j

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
XLIX.o

Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)
XLIX.w

Multiple organ dysfunction/failure (MODS/MOF)

L - Miscellaneous

L.y

Gingival hypertrophy

LI - Cardiovascular involvement / toxicity

LI.u

Cardiac- cardiorespiratory/pulmonary arrest
LI.z

Sinus arrest
LI.au

Giant cell myocarditis

LIII - Hemoglobinopathies - Abnormal hemoglobin states (acquired)

LIII.a

Methemoglobinemia

LV - Imaging

LV.b

Imaging: Ground-glass opacities (GGO) / shadowing

LVII - Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a

BAL: An excess proportion of lymphocytes

LVIII - Pathology

LVIII.m

Path: Lymphocytic interstitial pneumonia pattern
LVIII.aj

Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern)
LVIII.ay

Path: Pulmonary vasculitis other than capillaritis
LVIII.az

Path: Granulomatous pulmonary vasculitis
LVIII.bc

Path: Pulmonary capillaritis

LX - Neoplastic conditions

LX.b

Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)